Souderton, PA, USA – 11 February 2016 – Almac Clinical Technologies, part of the Almac Group, a global leader in technology for managing clinical trial patients and supplies has reached a major milestone by confirming that a global biotechnology company will be migrating to their newest generation Interactive Response Technology (IRT), IXRS® 3 platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Many of the leading research-focused healthcare organisations have reaped the time and cost saving benefits from migrating over to the IXRS 3 platform. Like many before them, this particular client partner will be provided with a customised platform that supports multiple integrations to meet specific needs throughout the each individual trial.
A tailored, intuitive, user-friendly interface will be employed to empower users, giving them a transparent view of data, reporting and information. This approach will help to mitigate the risk for error, as modifications can be made directly by the site, client or Almac.
Charlie Morris, VP, New Products & Services – Almac Clinical Technologies has commented: “We’ve worked closely with this client partner to design and implement key enhancements and integrations in the IXRS 3 platform to provide the right features to meet their needs, adapt to any protocol deviations, and match their experience. Our team of experts have worked to ensure a reduction in development time, while accelerating user/staff readiness.”
IXRS 3 was built to meet the market’s need for speed, adaptability, and mobile technology. The unique and customisable platform delivers faster, without compromising quality, allowing sponsors and CROs to effectively manage patient enrolment, drug assignment visits, and drug inventory throughout the lifecycle of a clinical trial. To learn more about Almac and IXRS 3, visit www.almacgroup.com.
